Meeting
2017 Gastrointestinal Cancers Symposium
Cost effectiveness of maintenance bevacizumab in patients with metastatic colorectal cancer.
Authors
Joel Lange
Medical College of Wisconsin, Milwaukee, WI
Joel Lange , Rahul Rajeev , T. Clark Gamblin , Kiran Turaga
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 718)
DOI
10.1200/JCO.2017.35.4_suppl.718
Abstract #
718
Poster Bd #
K6
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Bevacizumab (bev) for metastatic colorectal cancer (mCRC): A global cost-effectiveness analysis.
First Author: Daniel A. Goldstein
Poster
2014 ASCO Quality Care Symposium
Comparative effectiveness of antiangiogenesis inhibitors for second-line therapy of metastatic colorectal cancer.
First Author: Christina Xiaoyue Chen
Poster
2011 ASCO Annual Meeting
The cost-effectiveness of bevacizumab in combination with paclitaxel in first-line treatment of patients with metastatic breast cancer.
First Author: A. J. Montero
Poster
2023 ASCO Annual Meeting
Cost-effectiveness analysis of later-line therapies for metastatic colorectal cancer (mCRC) based on a novel methodology of network meta-analysis (NMA) of survival curves.
First Author: Mavis Obeng-Kusi